Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
If you remain depressed after trying antidepressants, you may be dealing with treatment resistant depression related to glutamate pathway issues, stress driven brain changes, medical or genetic factors, or misdiagnosis; there are several factors to consider, and the details below can shape your next steps.
Spravato esketamine nasal spray is a clinic based, rapid acting option for eligible adults that is used with an oral antidepressant and requires evaluation, enrollment, monitored induction and maintenance visits, and integration with therapy and lifestyle care, with risks and urgent warning signs explained below.
If you've been treated for depression but still don't feel better, you are not alone. Many people try one or even several antidepressants and continue to struggle. This experience is often called treatment-resistant depression (TRD). It does not mean you have failed. It means your brain may need a different approach.
In recent years, a newer option called Spravato treatment has offered hope for people whose depression has not improved with standard medications. Understanding why your brain may be "resisting" treatment—and what new steps are available—can help you make informed decisions with your doctor.
Traditional antidepressants (like SSRIs and SNRIs) mainly work on brain chemicals such as serotonin and norepinephrine. For many people, these medications are effective. But not everyone responds.
Here are some common reasons why depression may persist:
Depression does not involve only serotonin. Other systems—especially glutamate, the brain's main excitatory neurotransmitter—also play a major role. Standard antidepressants don't directly target glutamate.
Long-term stress can:
Traditional antidepressants may not fully reverse these changes.
Underlying issues like:
can make depression harder to treat.
Some people metabolize medications differently due to genetic factors. This can affect how well a drug works or how many side effects occur.
Conditions such as bipolar disorder, PTSD, ADHD, or anxiety disorders may overlap with depression. If the root condition isn't properly identified, treatment may fall short.
If you're unsure whether your symptoms align with depression or something related, taking a free Depression symptom checker can help you identify patterns and better articulate what you're experiencing when you speak with your healthcare provider.
Spravato treatment is a prescription nasal spray containing esketamine, a form of ketamine. It was approved by the U.S. Food and Drug Administration (FDA) for adults with treatment-resistant depression and for some individuals with major depressive disorder who have suicidal thoughts.
Unlike traditional antidepressants, Spravato treatment works on the glutamate system, specifically targeting NMDA receptors in the brain.
This different mechanism may help:
Spravato treatment is not a first-line medication. It is typically considered after at least two other antidepressants have not worked adequately.
Spravato treatment is administered as a nasal spray in a certified medical office or clinic.
Here's what makes it different:
After receiving Spravato treatment, patients remain in the clinic for monitoring—usually about two hours. This is because the medication can temporarily cause:
These effects typically resolve the same day.
If your doctor recommends Spravato treatment, here's the general process:
Your healthcare provider will:
Spravato treatment is available only through a restricted distribution system to ensure safe administration and monitoring.
Your schedule may vary based on how you respond.
Clinical trials have shown that Spravato treatment can significantly reduce depressive symptoms in people who have not responded to other antidepressants.
Some key findings from large, controlled studies:
However, it does not work for everyone. Some patients see major improvement. Others see partial improvement. A smaller group may not respond.
That's why close follow-up with your doctor is essential.
Spravato treatment may be appropriate if:
It is not suitable for everyone, including individuals with certain aneurysms or a history of specific vascular diseases. A thorough medical review is required.
While Spravato treatment is promising, it is not a simple fix.
Potential risks include:
Because of these risks, it must be administered under medical supervision.
It is also important to understand that Spravato treatment works best as part of a comprehensive plan, which may include:
Depression is rarely caused by one single factor. Even when Spravato treatment improves brain signaling, recovery often requires:
Medication can help stabilize mood. But long-term improvement often requires deeper work.
If you are experiencing:
You should seek immediate medical attention or contact emergency services. These symptoms can be life-threatening and require urgent care.
Always speak to a doctor about symptoms that feel severe, worsening, or dangerous.
If you're still feeling depressed despite treatment:
If your depression hasn't improved, it does not mean you are broken or beyond help. It may mean your brain needs a different strategy.
Spravato treatment represents a newer, science-backed option for people whose depression has resisted standard medications. By targeting a different brain system, it offers a new pathway toward recovery.
That said, it is not a cure-all. It requires careful screening, in-clinic monitoring, and ongoing medical oversight. The best outcomes happen when medication is combined with therapy and healthy lifestyle changes.
Most importantly: do not try to manage severe depression alone. Speak to a qualified healthcare professional about any persistent, worsening, or potentially life-threatening symptoms. There are options—and asking about them is a strong and practical step forward.
(References)
* Chang H, Han S, Chang L, Hu J, Liu D. Neurobiology of Treatment-Resistant Depression: Pathophysiology and Therapeutic Strategies. Front Psychiatry. 2022 Mar 30;13:854938. doi: 10.3389/fpsyt.2022.854938. PMID: 35432655; PMCID: PMC9004122.
* Singh A, Singh AK, Singh AP, Singh B, Singh S, Agrawal V. Efficacy and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. Cureus. 2023 Apr 1;15(4):e36979. doi: 10.7759/cureus.36979. PMID: 37131806; PMCID: PMC10150935.
* Krystal JH, Sanacora G, Duman RS. Mechanisms of Ketamine and Esketamine in Treatment-Resistant Depression. Neuropsychopharmacology. 2022 Oct;47(10):1786-1798. doi: 10.1038/s41386-022-01402-4. Epub 2022 Aug 23. PMID: 35999335; PMCID: PMC9528659.
* Papakostas GI, Katragkou A, Ilias I, Psaridi M, Chatzigeorgiou G. Clinical Guidance for the Use of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression: A Narrative Review. Adv Ther. 2023 Feb;40(2):494-511. doi: 10.1007/s12325-022-02384-z. Epub 2022 Nov 22. PMID: 36414774; PMCID: PMC9936894.
* Hameed U, Nisar A, Khawaja S, Khan AA, Rind B, Gul M, Khan AR. Pharmacological and Nonpharmacological Treatments for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Cureus. 2024 Jan 13;16(1):e52187. doi: 10.7759/cureus.52187. PMID: 38352601; PMCID: PMC10864273.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.